Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 221

1.

Other Antidepressants.

Schwasinger-Schmidt TE, Macaluso M.

Handb Exp Pharmacol. 2018 Sep 8. doi: 10.1007/164_2018_167. [Epub ahead of print]

PMID:
30194544
2.

Effects of α2A Adrenoceptors on Norepinephrine Secretion from the Locus Coeruleus during Chronic Stress-Induced Depression.

Wang B, Wang Y, Wu Q, Huang HP, Li S.

Front Neurosci. 2017 May 1;11:243. doi: 10.3389/fnins.2017.00243. eCollection 2017.

3.

Asenapine modulates mood-related behaviors and 5-HT1A/7 receptors-mediated neurotransmission.

Delcourte S, Abrial E, Etiévant A, Rovera R, Arnt J, Didriksen M, Haddjeri N.

CNS Neurosci Ther. 2017 Jun;23(6):518-525. doi: 10.1111/cns.12698. Epub 2017 Apr 17.

PMID:
28417559
4.

Role of cortical alpha-2 adrenoceptors in alcohol withdrawal-induced depression and tricyclic antidepressants.

Getachew B, Hauser SR, Csoka AB, Taylor RE, Tizabi Y.

Drug Alcohol Depend. 2017 Jun 1;175:133-139. doi: 10.1016/j.drugalcdep.2017.03.004. Epub 2017 Apr 4.

5.

The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies.

Amare AT, Schubert KO, Klingler-Hoffmann M, Cohen-Woods S, Baune BT.

Transl Psychiatry. 2017 Jan 24;7(1):e1007. doi: 10.1038/tp.2016.261. Review.

6.

Potentials of Mangifera indica in the treatment of depressive-anxiety disorders: possible mechanisms of action.

Ishola IO, Awodele O, Eluogu CO.

J Complement Integr Med. 2016 Sep 1;13(3):275-287. doi: 10.1515/jcim-2015-0047.

PMID:
27276531
7.

AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

Ivachtchenko AV, Lavrovsky Y, Okun I.

J Alzheimers Dis. 2016 May 25;53(2):583-620. doi: 10.3233/JAD-151146. Review.

8.

Alpha2C-adrenoceptor Del322-325 polymorphism and risk of psychiatric disorders: significant association with opiate abuse and dependence.

Rivero G, Martín-Guerrero I, de Prado E, Gabilondo AM, Callado LF, García-Sevilla JA, García-Orad Á, Meana JJ.

World J Biol Psychiatry. 2016 Jun;17(4):308-15. doi: 10.3109/15622975.2016.1142608. Epub 2016 Mar 23.

PMID:
27007576
9.

α2 Adrenergic Receptor Trafficking as a Therapeutic Target in Antidepressant Drug Action.

Cottingham C, Ferryman CJ, Wang Q.

Prog Mol Biol Transl Sci. 2015;132:207-25. doi: 10.1016/bs.pmbts.2015.03.007. Epub 2015 Apr 16. Review.

PMID:
26055060
10.

Noradrenergic modulation of glutamate-induced excitatory responses in single neurons of the red nucleus: an electrophysiological study.

Bronzi D, Licata F, Li Volsi G.

Neuroscience. 2015 Aug 6;300:360-9. doi: 10.1016/j.neuroscience.2015.05.038. Epub 2015 May 23.

PMID:
26012489
11.

Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.

Kato M, Serretti A, Nonen S, Takekita Y, Wakeno M, Azuma J, Kinoshita T.

Transl Psychiatry. 2015 Feb 24;5:e513. doi: 10.1038/tp.2015.6.

12.

Dysfunctional inhibitory mechanisms in locus coeruleus neurons of the wistar kyoto rat.

Bruzos-Cidón C, Llamosas N, Ugedo L, Torrecilla M.

Int J Neuropsychopharmacol. 2015 Jan 13;18(7):pyu122. doi: 10.1093/ijnp/pyu122.

13.

Decreased in vivo α2 adrenoceptor binding in the Flinders Sensitive Line rat model of depression.

Landau AM, Phan JA, Iversen P, Lillethorup TP, Simonsen M, Wegener G, Jakobsen S, Doudet DJ.

Neuropharmacology. 2015 Apr;91:97-102. doi: 10.1016/j.neuropharm.2014.12.025. Epub 2015 Jan 7.

PMID:
25576372
14.

Tricyclic antidepressants exhibit variable pharmacological profiles at the α(2A) adrenergic receptor.

Cottingham C, Percival S, Birky T, Wang Q.

Biochem Biophys Res Commun. 2014 Aug 29;451(3):461-6. doi: 10.1016/j.bbrc.2014.08.024. Epub 2014 Aug 12.

15.

Increased α2- and β1-adrenoceptor densities in postmortem brain of subjects with depression: differential effect of antidepressant treatment.

Rivero G, Gabilondo AM, García-Sevilla JA, La Harpe R, Callado LF, Meana JJ.

J Affect Disord. 2014;167:343-50. doi: 10.1016/j.jad.2014.06.016. Epub 2014 Jun 18.

PMID:
25020269
16.

Pain exacerbates chronic mild stress-induced changes in noradrenergic transmission in rats.

Bravo L, Torres-Sanchez S, Alba-Delgado C, Mico JA, Berrocoso E.

Eur Neuropsychopharmacol. 2014 Jun;24(6):996-1003. doi: 10.1016/j.euroneuro.2014.01.011. Epub 2014 Jan 18.

PMID:
24491949
17.

Noradrenergic blockade and memory in patients with major depression and healthy participants.

Kuffel A, Eikelmann S, Terfehr K, Mau G, Kuehl LK, Otte C, Löwe B, Spitzer C, Wingenfeld K.

Psychoneuroendocrinology. 2014 Feb;40:86-90. doi: 10.1016/j.psyneuen.2013.11.001. Epub 2013 Nov 12.

PMID:
24485479
18.

Meranzin hydrate exhibits anti-depressive and prokinetic-like effects through regulation of the shared α2-adrenoceptor in the brain-gut axis of rats in the forced swimming test.

Xie Y, Huang X, Hu SY, Qiu XJ, Zhang YJ, Ren P, Wang Y, Ji H, Zhang CH, Xie WB, He J, Xie MZ, Huang HY, Liu ZQ, Zhou HH.

Neuropharmacology. 2013 Apr;67:318-25. doi: 10.1016/j.neuropharm.2012.10.003. Epub 2012 Oct 10.

PMID:
23063894
19.

α2 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy.

Cottingham C, Wang Q.

Neurosci Biobehav Rev. 2012 Nov;36(10):2214-25. doi: 10.1016/j.neubiorev.2012.07.011. Epub 2012 Aug 13. Review.

20.

Chronic pain leads to concomitant noradrenergic impairment and mood disorders.

Alba-Delgado C, Llorca-Torralba M, Horrillo I, Ortega JE, Mico JA, Sánchez-Blázquez P, Meana JJ, Berrocoso E.

Biol Psychiatry. 2013 Jan 1;73(1):54-62. doi: 10.1016/j.biopsych.2012.06.033. Epub 2012 Jul 31.

PMID:
22854119

Supplemental Content

Loading ...
Support Center